J&J Medical Connect
IMAAVY™

(nipocalimab-aahu)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY™ (nipocalimab-aahu)
Medical Information

IMAAVY - Use in Patients with Cold Autoimmune Hemolytic Anemia

Last Updated: 09/01/2026

SUMMARY

  • The company cannot recommend any practices, procedures, or usage of IMAAVY that deviate from the approved labeling.
  • In the ENERGY phase 2/3 clinical study, patients diagnosed with cold antibody autoimmune hemolytic anemia (AIHA) or cold agglutinin syndrome were excluded from the trial.1,2

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) conducted on 31 August 2026 did not identify any relevant citations pertaining to this topic.

 

References

Show
1 Fattizzo B, Murakhovskaya I, Ueda Y, et al. Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study. [published online ahead of print August 28, 2026]. Blood. 2026. doi:10.1182/blood.2026034036.  
2 Fattizzo B, Murakhovskaya I, Ueda Y, et al. Supplement to: Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study. [published online ahead of print August 28, 2026]. Blood. 2026. doi:10.1182/blood.2026034036.  

Would you like to clear and leave your conversation? Message history will be lost.